Daiichi Sankyo and Merck dose first subject in ovarian cancer trial

cafead

Administrator
Staff member
  • cafead   Apr 04, 2024 at 11:02: AM
via Daiichi Sankyo and Merck (MSD) have dosed the first subject in the global Phase II/III REJOICE-Ovarian01 clinical trial of raludotatug deruxtecan (R-DXd) in platinum-resistant, ovarian cancer patients.

article source